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INTRODUCTION
Male (NZW  BXSB)F1 (W/BF1) mice develop acute
autoimmune disease similar to human systemic lupus ery-
thematosus (SLE) and subsequently express degenerative
coronary vascular disease (CVD) with myocardial infarc-
tions (MIs) that occur at a 4-fold higher rate than is encoun-
tered in other autoimmune mouse strains [1-4]. The pro-
duction of anti–double stranded DNA (anti-dsDNA),
platelet-associated anticardiolipin (anti-CLP), and
antiplatelet autoantibodies accounts for persistently elevated
levels of circulating immune complexes and deposition of
the complexes in the subendothelium of the coronary vascu-
lature. The autoantibody titers increase with age and are
directly correlated to the increased incidence of multiple
MIs and mortality in mice of this strain.
The pathology and progression of autoimmune disease
have been well characterized in the W/BF1 mouse after
12 weeks of age. Previous studies have examined the use of
T-cell–depleted bone marrow (TCDM) to prevent CVD in
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ABSTRACT
This project was designed to investigate the application of bone marrow transplantation to a progressive and ulti-
mately fatal systemic autoimmune disease. Male (NZW  BXSB)F1 (W/BF1) mice develop acute systemic autoim-
mune disease characterized by degenerative coronary vascular disease (CVD) with myocardial infarctions, hyperten-
sion, thrombocytopenia, glomerulonephritis, and persistently elevated levels of circulating immune complexes.
After preliminary studies established the onset of disease between 10 and 12 weeks of age, 6- to 8-week-old male
W/BF1 mice were targeted for transplantation with either T-cell–depleted bone marrow or purified hematopoietic
stem cells from haploidentical B6C3/F1 mice. Posttransplantation flow cytometric analysis of splenocytes demon-
strated donor phenotypes in W/BF1 recipient mice that had received T-cell–depleted marrow or hematopoietic stem
cell preparations (lineage negative, CD71 negative) from B6C3/F1 donors. Survival of W/BF1 mice transplanted with
bone marrow from normal B6C3/F1 donors was very high, and assessment at 100 days after transplantation revealed
reduction in onset and severity of disease. Autoantibodies to cardiolipin and double-stranded DNA were markedly
reduced to levels present in normal mice. Immunohistochemistry of heart and kidney tissue revealed significant
amelioration of degenerative CVD and glomerulonephritis in the majority of W/BF1 recipients of marrow trans-
plants from B6C3/F1 donors. All engrafted W/BF1 mice displayed normal immunologic competence 100 days
posttransplantation.
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this model [5]. Thus, the present study investigated whether
stem cell–puriﬁed bone marrow (BM), in addition to TCDM,
could be used to fully reconstitute the immune system of
male W/BF1 mice before the onset of progressive and ulti-
mately fatal systemic autoimmune disease, and thereby also to
prevent CVD and the associated mortality of mice of this
strain. Haploidentical male B6C3/F1 mice served as normal,
nonautoimmune donors. Preliminary studies established that
between the ages of 6 and 8 weeks, male W/BF1 mice are free
from autoimmune disease; onset of disease occurs between 10
and 12 weeks of age and progresses rapidly thereafter.
W/BF1 mice suffer from autoimmune-associated hyper-
tension that has been found to be unrelated to certain host
factors, such as hormones, diet, stress, or steroids [6,7].
Thrombocytopenia in these mice arises from the removal and
destruction of antibody-bound platelets by the reticuloen-
dothelial system, particularly in the spleen and liver [8,9]. The
production of autoantibodies to dsDNA, platelets, and CLP,
as well as other platelet-bound autoantibodies, accounts for
persistently elevated levels of circulating immune complexes.
Deposition of these complexes in the subendothelium of the
vasculature leads to occlusive vascular disease in the heart,
kidney, and other tissues [6,10,11]. In the kidneys, mesangial
proliferation, as well as endothelial proliferation and some
vascular occlusion, leads to rapidly progressing renal malfunc-
tion. The autoantibody titers increase with age and are
directly correlated to the increased incidence of multiple MIs
and ultimately to early mortality [8,11-13]. Large major coro-
nary arteries usually remain relatively undamaged, but death
results from the cumulative effects of multiple small MIs.
Proliferative thickening of the intima and endothelium, in the
absence of obvious inflammatory infiltrates, gives rise to
occlusive thrombi in the intramyocardial arterioles and to the
subsequent necrosis [3,4,14].
Platelets from female W/BF1 or BALB/c donors are
immediately cleared by circulating antiplatelet antibodies
when these elements are transferred to male W/BF1 recipi-
ents. Allogeneic BM transplants from BALB/c donors to
adult W/BF1 mice ameliorated the progression of thrombo-
cytopenia [15,16]. Likewise, transplantation of W/BF1 BM
into autoimmune-resistant mouse strains leads to the devel-
opment of thrombocytopenia and lupus nephritis. Immuno-
suppression by treatment with cytoxan prevents SLE and
CVD. Multiple studies have provided evidence that the
defect resulting in autoimmunity resides in the stem cell
compartment and that replacement of defective stem cells
via bone marrow transplantation (BMT) may be an effective
means of preventing the development of autoimmune dis-
eases or even, in some instances, of curing these diseases
after they have been launched [6,9,17,18].
MATERIALS AND METHODS
Animals
Four-week-old male W/BF1 and 10- to 12-week-old
male B6C3/F1 or BALB/c or 20- to 24-week-old MRL/lpr
lpr (MRL/L) mice were obtained from Jackson Laboratory
(Bar Harbor, ME). All animals were maintained under spe-
ciﬁc pathogen-free conditions in a clean, conventional envi-
ronment in an American Association for Accreditation of
Laboratory Animal Care (AAALAC)-accredited facility.
W/BF1 mice were transplanted at 6 to 8 weeks of age, and
B6C3/F1 were transplanted at 12 to 14 weeks of age.
Dimethyl Myleran Preparation
Dimethyl myleran (DMM) (courtesy of C.D. Buckner,
Seattle, WA), which provides myeloablation without
immunosuppression, was provided in 50-mg bottles. Five
milliliters of DMM was dissolved in 100% dimethyl sulfox-
ide (DMSO), divided into 1-mL aliquots, and stored at
–80°C. One-milliliter aliquots were dissolved in 9 mL warm
(37°C) phosphate-buffered saline (PBS) for a ﬁnal solution
of 1 mg/mL DMM in PBS, 10% DMSO. The solution was
divided into 3-mL aliquots and stored at –20°C until use.
Preparation of BMT Recipients 
Transplant recipients were prepared 48 hours before
transplantation by total body irradiation with 8.0 Gy from a
137Cs source. Twenty-four hours after total body irradiation,
mice were also given 0.2 mg DMM via the retroorbital
plexus (approximately 10 mg/kg). All recipients were main-
tained in a laminar containment facility and fed sterilized
food and acidiﬁed water.
BM Harvesting
All BM samples were prepared on ice using sterile tech-
niques throughout. Donor mice were killed by CO2 inhala-
tion immediately before harvest. The tibias and femurs were
placed into ice-cold RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), 1% glutamine, 1%
penicillin/streptomycin, and 1% HEPES buffer, and mar-
row was flushed with ice-cold, supplemented RPMI. The
BM suspension was repeatedly resuspended to obtain a fully
dispersed, single-cell suspension, strained through 70-µm
nylon ﬁlters to remove debris, and kept on ice.
TCDM Preparation
Whole bone marrow (WBM) was pelleted in a cen-
trifuge at 500g and 4°C for 5 minutes. The supernatant was
removed, and aThy 1.2 antibody (PharMingen, San Diego,
CA) was added to the WBM pellet at 1 µg per 5  106 cells
and allowed to stand on ice for 30 minutes. Selected low-
toxicity rabbit complement (Cedarlane, Hornby, Ontario,
Canada) was diluted to a ﬁnal dilution of 1:20, and 1 mL per
5  107 cells was added and allowed to incubate for 45 min-
utes at 37°C to yield TCDM. After incubation, cells were
washed twice with supplemented RPMI and counted.
Stem Cell Purification
Hematopoietic stem cells were puriﬁed on a discontinu-
ous Percoll gradient (Pharmacia, Piscataway, NJ), as
described below, at pH 7.0 and 2.300 mOsm/kg. Cell counts
and viability were determined using a hemacytometer and
trypan blue dye exclusion for WBM suspended in supple-
mented RPMI. The BM suspension was centrifuged for
5 minutes at 500g at 4°C in a 15-mL conical gradient tube.
The supernatant was discarded, and 3 mL of 100%
(1.094 g/mL) Percoll per mouse was added to the pellet,
ﬂushed to resuspend the cells, mixed using a vortex mixer,
layered with the remaining Percoll, and placed on ice for
10 minutes. Gradient tubes were then centrifuged at 2000g
for 36 minutes at 4°C. Following centrifugation, fraction 2,
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between 1.059 and 1.072 g/mL, was collected by Pasteur
pipette and placed into new gradient tubes. Cell count and
viability for fraction 2 were recorded. The gradient tubes
were filled with supplemented RPMI, mixed, and cen-
trifuged at 500g and 4°C for 10 minutes. Cells were washed
a second time with supplemented RPMI as before. The pel-
let was resuspended to a concentration of 1  107 to 5  107
cells/mL in supplemented RPMI.
A monoclonal antibody (mAb) cocktail was prepared
using at least 5 to 10 µg/mL of cell suspension for each
mAb. Antibodies used included anti-CD4 (L3T4), anti-CD8
(Lyt2), anti-myelomonocyte (Mac1), anti-B (B220), anti-
granulocyte (Gr1), and anti–transferrin receptor (CD71)
(PharMingen). The total volume of mAb was added to the
cell suspension, mixed gently to resuspend the pellet, and
incubated on ice for 30 min. After incubation, the gradient
tube was ﬁlled with supplemented RPMI and centrifuged at
500g for 5 minutes. Cells were washed twice with RPMI,
and the supernatant was discarded.
Stem cells were purified from fraction 2 via immuno-
magnetic bead separation (Dynal, Lake Success, NY) by
selection of lineage-negative cells. For negative selection, the
cell-to-bead ratio was 1:10. Immunomagnetic beads were
washed with 1 mL supplemented RPMI. Supplemented
RPMI was added to the beads to make approximately 400 to
500 µL. The washed pellet was mixed with one third of the
washed beads by using a vortex mixer and incubated on ice
for 30 minutes, mixing every 5 minutes. After incubation, the
tube was ﬁlled to approximately one half with supplemented
RPMI and mixed by inversion. Immunomagnetic bead-
rosetted cells were removed with a magnet. The supernatant,
containing negatively selected cells, was decanted and saved.
Bead puriﬁcation was repeated, as before, with the remaining
two thirds of the beads.
Bone Marrow Transplantation
Prepared TCDM or stem cell preparations were trans-
planted via the retroorbital plexus 1 day after DMM treat-
ment. TCDM was transplanted at 2  107 to 4  107
cells/mouse for allogeneic transplants and 1  107 to 3 
107 cells for syngeneic controls. Hematopoietic stem cell
(HSC) preparations were transplanted at 3  105 to 6  105
cells/mouse for allogeneic transplants and 1  105 to 3 
105 cells for syngeneic controls.
Flow Cytometric Analysis
The spleen cell suspension was centrifuged at 500g and
4°C for 5 minutes. Cell suspensions (1  106 cells) were
incubated for 30 minutes at 4°C with appropriate mAbs,
washed with Hanks’ balanced salt solution (HBSS), and cen-
trifuged at 300g for 5 minutes. The pellet was resuspended
in 500 µL PBS, strained through nylon membrane, and ﬁxed
with 50 µL 4% paraformaldehyde (PFA) per 1  106
cells/500 µL PBS. Flow cytometric analysis was performed
using an EPICS Elite (Coulter, Hialeah, FL).
Anti-CLP and Anti-dsDNA Assays
Antibody assays were performed as previously described
[14,15]. Brieﬂy, peripheral blood was collected from control
and experimental mice via the retroorbital plexus, allowed to
clot, and centrifuged. The serum was collected and frozen.
CLP (Sigma, St. Louis, MO) was diluted to 100 µg/mL in
0.01 mol/l PBS, pH 7.4. Calf thymus dsDNA (Sigma) was
diluted to 10 µg/mL in PBS. In each well of a microtiter
plate, 50 µL CLP solution or 100 µL DNA solution was
incubated overnight at 4°C. All wells were washed 3 times
with PBS-T (PBS with 0.05% Tween 20) and blotted dry. To
block nonspeciﬁc binding, 200 µL 10% FBS was added to
each CLP well and 20 µL of 2% bovine serum albumin
(BSA) was added to each DNA well. All plates were incu-
bated for 1 hour at 37°C. All wells were washed 3 times with
PBS-T. In each microtiter well, 50 µL of sample or control
sera that had been diluted 1:100 with PBS-T was placed,
incubated for 1 hour at room temperature for CLP or at
37°C for the DNA analyses, then washed 3 times as before.
Then, 100 µL alkaline phosphatase–conjugated goat anti-
mouse immunoglobulin (Ig) G (Sigma) that had been diluted
1:1000 with PBS-T was placed in each well, incubated for
1 hour at 37°C, and washed 3 times as before.
To each well was added 100 µL of alkaline phosphatase
enzyme substrate (p-nitrophenyl phosphate) (Sigma) that
had been diluted to 1 mg/mL in diethanolamine buffer. The
wells were incubated for 30 to 40 minutes at room tempera-
ture. The reaction was stopped by adding 50 µL of 3N
NaOH to each well. Optical absorbance was measured on a
Dynatech ELISA reader at 405 nm.
Histological Analysis
Recipient mice were killed by CO2 inhalation at 100 days
posttransplantation. Designated organs (heart, kidneys, liver,
and lung) were harvested and placed into 4% PFA-PBS for
4 hours. An increasing gradient of 10%, 15%, 20%, and
25% sucrose in PBS was used to replace PFA-PBS with 4
hours allowed for each phase of the gradient. The organs
were ﬂash-frozen on a dry ice/acetone solution, serially cut
in 4- to 6-µm slices on a Cryostat Microtome (Sakura
Finetek, Torrance, CA), mounted on poly-prep (poly-L-
lysine–coated) slides (Sigma), and stored at –80°C.
Selected slides were stained with either periodic acid-Schiff
(PAS) reagent or hematoxylin and eosin. Additional slides were
prepared as follows. Intrinsic peroxidase activity was blocked
on mounted sections with 100 mL CH3OH plus 1 mL 30%
H2O2 at room temperature for 30 minutes. Slides were incu-
bated with 200 to 300 µL of 10% goat serum in PBS at room
temperature for 30 minutes. Added to each slide was 200 to
300 µL of either a 1:1000 dilution of biotinylated mouse anti-
IgG in 1% BSA or a 1:500 dilution of biotinylated mouse anti-
IgM (Vector Labs, Burlingame, CA). Slides were incubated
overnight at 4°C, then incubated with 200 to 300 µL avidin-
biotin solution at room temperature for 30 minutes, and cov-
ered with diaminobenzidine solution (DAB) (Sigma) (10 mL
H2O plus 67 µL 30% H2O2, 10 mg DAB plus 10 mL
0.1 mol/L Tris buffer, pH 7.2, mixed and ﬁltered) for 4 to
5 minutes. Each slide was individually counterstained in hema-
toxylin for 30 to 60 seconds.
CVD was classiﬁed from 0 to 3+, according to the method
described by Berden et al. [12]. Grade 1 indicates minimal
PAS-positive deposits along and within 1 coronary vascular
wall in a single serial section of the heart; grade 2 indicates
PAS-positive deposits with narrowing of the lumen in 2 or 3
coronary vessels; grade 3 indicates 4 or more affected coronary
vessels per serial section of the heart. MIs are often associated
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with CVD grades 2 and 3. The degree of glomerulonephritis
was classiﬁed from 0 to 3, according to the method described
by Berden et al. [12] as modiﬁed by Mizutani et al. [15]. Grade
1 indicates thickening and increased cellularity of the
mesangium; grade 2 indicates increased mesangial cellularity
plus increased cellularity of glomerular endothelium, inﬂam-
matory inﬁltrates, and presence of capsular adhesions; grade 3
indicates severe glomerular destruction with tubular cast for-
mation and crescent development.
Mitogen Assays
A total of 2.5  105 cells from single spleen cell suspen-
sions in supplemented RPMI were added to each well of a
flat-bottomed 96-well tissue culture plate and cultured in
triplicate with 100 µL of either concanavalin A (ConA)
(10 µg/mL) or lipopolysaccharide (LPS) (20 µg/mL). Cul-
tures were incubated for 48 hours at 37°C and 5% CO2.
After incubation, cells were pulsed with 0.5 µCi [3H]thymi-
dine (in 25 µL supplemented RPMI) and incubated for
12 hours, as before. After incubation, [3H]thymidine uptake
was measured using a liquid scintillation spectrometer.
Stimulation index value was calculated as
mean cpm of the BMT recipient + ConA or LPS
mean cpm of recipient + RPMI
.
Mixed Lymphocyte Reaction
Spleen cell suspensions selected to serve as stimulator
cells were irradiated at 30 Gy. A total of 5  105 stimulator
spleen cells were placed into each well of a U-bottomed 96-
well tissue culture plate and cultured in triplicate with 5 
105 responder spleen cells. The plates were incubated at
37°C, 5% CO2 for 4 days. Then the cells were pulsed with
1 µCi [3H]thymidine (in 25 µL HBSS) and incubated as
before for 24 hours. After incubation, [3H]thymidine uptake
was measured as previously described. Stimulation index
value was calculated as
mean cpm of the BMT recipient + stimulator cells
mean cpm of recipient + autologous cells
.
Sheep Red Blood Cell Assay for Primary Antibody
Response
Sheep red blood cells (SRBCs) were obtained by
venipuncture from an adult healthy donor sheep, washed,
and resuspended in HBSS/2% FBS to a concentration of 2%
if used for injection, 1% if used for assay. Mice that had pre-
viously been given a BMT were injected intraperitoneally
with 0.5 mL of 2% SRBC in HBSS at 100 days after trans-
plantation. Five days after SRBC injection, peripheral blood
was collected and the serum separated and frozen at –20°C.
Twenty microliters of HBSS/FBS was placed in each
well of a 96-well, round-bottomed microtiter plate, allowing
for 1 row of blanks. To the ﬁrst well, 20 µL of sample serum
was added and mixed by pipette. Twenty microliters was
removed from the first well and transferred to the second
well. Serial dilutions were continued in this manner through
the last well. The final 20 µL from the last well was dis-
carded. HBSS was added to the blanks. To each well, 20 µL
1% SRBC was added, and the microtiter plate was allowed
to incubate at room temperature for 1 hour. Results were
expressed as the titer of the last well showing agglutination.
Statistical Analysis
Statistical significance was analyzed using the Student
t test.
RESULTS
Analysis of Bone Marrow Engraftment of W/BF1
Recipients
Recipient mice were killed by CO2 inhalation at 100 days
posttransplantation. Two thirds (67%) of the W/BF1 mice that
received TCDM from haploidentical B6C3/F1 donors survived
to 100 days posttransplantation (Figure 1). Allogeneic trans-
plantations of HSC preparations resulted in 94% survival.
Flow cytometric analysis was performed on spleen cells
of W/BF1 BM recipients to determine the level of engraft-
ment. Normal B6C3/F1, W/BF1, and BALB/c mice that had
not received BM transplants served as controls. B6C3/F1
mice possess a b/k haplotype, whereas W/BF1 mice are b/z.
BALB/c (d/d) mice served as double-negative controls.
Because there is no available antibody to H-2Kz, engraftment
was established by the presence or absence of H-2Kk in the
spleen sample. Samples were also examined for the presence
of H-2Kb as a control standard. With the exception of the
BALB/c negative controls, H-2Kb was detectable in all mice
with or without transplantation. H-2Kk was present in all
B6C3/F1 control mice but not in W/BF1 or BALB/c controls
(Table 1). H-2Kk was present in 5 of 6 of the W/BF1 mice
given allogeneic TCDM, for an 83% engraftment rate, and
was not detected in mice transplanted with syngeneic
TCDM. H-2Kk was present in 8 of 9 of the W/BF1 mice that
received allogeneic HSC preparations, for an 89% engraft-
ment rate, and was not detected any of the mice transplanted
with syngeneic HSC preparations (Table 1).
Analysis of Immunologic Reconstitution of W/BF1
Recipients
Cellular immunologic reconstitution in W/BF1
recipients was analyzed by response to mitogenic challenge.
Figure 1. Survival of W/BF1 recipients of bone marrow preparations.
Results are reported as percentage survival to 100 days posttransplanta-
tion. TCDM indicates T-cell–depleted bone marrow; HSC, hemato-
poietic stem cell.
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Incorporation of [3H]thymidine by spleen cells from nor-
mal B6C3/F1 or BALB/c mice stimulated with ConA meas-
ured 36.4 ± 16.2  103 cpm and 54.0 ± 10.6  103 cpm,
respectively (Figure 2). Spleen cells from aged W/BF1 mice
demonstrated a muted response to ConA stimulation of
19.3 ± 7.7  103 cpm. W/BF1 recipients of both allogeneic
TCDM, at 57.0 ± 3.8  103 cpm, and HSC preparations, at
46.3 ± 16.0  103 cpm, demonstrated enhanced responsive-
ness to ConA stimulation compared with aged W/BF1 mice
and were not signiﬁcantly different from BALB/c controls.
However, W/BF1 recipients of syngeneic transplants,
regardless of preparative protocol, produced only limited
ConA responses.
Assays of normal B6C3/F1 and BALB/c mice stimulated
with LPS measured 6.1 ± 1.7  103 and 4.8 ± 2.1 
103 cpm, respectively (Figure 3). Aged W/BF1 mice demon-
strated a normal response to LPS stimulation of 7.1 ± 1.4 
103 cpm. W/BF1 recipients of both allogeneic TCDM, at
7.7 ± 0.7  103 cpm, and HSC preparations, at 7.2 ± 2.7 
103 cpm, demonstrated normal responsiveness to LPS stim-
ulation compared with controls. Additionally, recipients of
syngeneic transplants, regardless of preparative protocol,
produced normal LPS responses.
As a means of evaluating tolerance to self-antigens and
reactivity to unrelated antigens, transplant recipients were
subjected to mixed lymphocyte reactions. Spleen samples
from recipients were assayed for reactivity to donor, recipi-
ent, and unrelated third-party spleen samples. Results were
reported as a stimulation index in which the index value was
calculated as 
mean cpm of the BMT recipient + stimulator cells
mean cpm of recipient + autologous cells
.
W/BF1 mice elicited a response from normal B6C3/F1 mice
that was more than 2-fold higher than the baseline value
(autologous stimulation, 1.0), whereas BALB/c mice elicited
a 3-fold response. However, when challenged with B6C3/F1
stimulator cells, W/BF1 demonstrated a muted reaction of
1.4 ± 0.3. Response by W/BF1 to BALB/c challenge was
Figure 2. ConA responses of W/BF1 recipients of bone marrow
preparations. A total of 2  106 spleen cells were challenged with 1 µg
ConA. Proliferation was measured by uptake of [3H]thymidine. Results
are reported as mean cpm ± 1 SD. TCDM indicates T-cell–depleted
bone marrow; HSC, hematopoietic stem cell.
Figure 3. LPS responses of W/BF1 recipients of bone marrow prepa-
rations. A total of 2  106 spleen cells were challenged with 2 µg LPS.
Proliferation was measured by uptake of [3H]thymidine. Results are
reported as mean cpm ± 1 SD. TCDM indicates T-cell–depleted bone
marrow; HSC, hematopoietic stem cell. 
Table 1. Flow Cytometric Analysis of W/BF1 Recipients of Bone Marrow Preparations*
n Engraftment, % H-2Kb, % H-2Kk, %
Control
B6C3/F1 8 — 76.38 ± 19.13 74.23 ± 18.10
W/BF1 6 — 75.78 ± 13.98 1.54 ± 1.13
BALB/c 7 — 3.20 ± 1.34 0.62 ± 0.65
TCDM transplantation
B6C3/F1→ W/BF1 6 83 48.01 ± 18.37 67.31 ± 32.25
W/BF1→ W/BF1 1 100 61.87 1.94
HSC transplantation
B6C3/F1→ W/BF1 9 89 62.67 ± 24.96 64.50 ± 24.48
W/BF1→ W/BF1 2 100 61.95 1.68
*Individual samples were stained with the indicated ﬂuorescein isothiocyanate–conjugated monoclonal antibodies. Results are reported as the
percentage of total cell events. TCDM indicates T-cell–depleted bone marrow; HSC, hematopoietic stem cell.
TCDM HSC
(n = 3)
W/BF1→W/BF1
TCDM HSC
(n = 4)(n = 8)
B6C3F1→W/BF1
B6C3/F1 W/BF1 BALB/c
(n = 6)
TCDM HSC
(n = 3)
W/BF1→W/BF1
TCDM HSC
(n = 4)(n = 8)
B6C3F1→W/BF1
B6C3/F1 W/BF1 BALB/c
(n = 6)
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more than 2-fold the auto-index value. Normal BALB/c
mice responded vigorously to both W/BF1 and B6C3/F1
stimulation, with index values of 3.4 ± 1.7 and 2.3 ± 0.7,
respectively (Table 2).
W/BF1 recipients of allogeneic TCDM were tolerant of
donor antigens, tolerant of self-antigens, and responsive to
unrelated third-party antigens (Table 2). However, W/BF1
recipients of syngeneic TCDM were tolerant of both donor
and recipient antigens and demonstrated a reduced respon-
siveness to third-party stimulation. W/BF1 recipients of allo-
geneic HSC preparations were tolerant of donor antigens,
tolerant of self-antigens, and reactive to unrelated third-party
antigens. However, W/BF1 recipients of syngeneic TCDM
were tolerant of donor, recipient, and third-party antigens.
Primary antibody responsiveness was evaluated by
agglutination of SRBC in a microtiter assay. Both normal
B6C3/F1 and BALB/c mice demonstrated a vigorous
response to SRBC, with a mean titer of 512 for B6C3/F1
and a mean titer of 741 for BALB/c. However, aged W/BF1
controls, which expressed impressive autoimmunity, lacked
measurable responses to SRBC (Figure 4). In marked con-
trast to aged W/BF1 controls, W/BF1 mice that received
allogeneic TCDM from B6C3/F1 donors developed a mean
titer of 18, whereas those that received HSC preparations
developed a mean titer of 118. Of 6 W/BF1 recipients of
syngeneic BM, 5 did not mount an antibody response to
SRBC. The sole exception was a syngeneic recipient of an
HSC preparation with a titer of 8.
Table 2. Mixed Lymphocyte Reaction Stimulation Index of W/BF1 Recipients of Bone Marrow Preparations*
Stimulator
Responder n B6C3/F1 W/BF1 BALB/c
Control
B6C3/F1 7 1.0 2.5 ± 1.3 3.0 ± 1.4
W/BF1 7 1.4 ± 0.3 1.0 2.3 ± 0.5
BALB/c 7 3.4 ± 1.7 2.3 ± 0.7 1.0
TCDM transplantation
B6C3/F1→ W/BF1 7 0.9 ± 0.2 0.9 ± 0.2 2.6 ± 1.0
W/BF1→ W/BF1 2 1.2 0.9 1.5
HSC transplantation
B6C3/F1→ W/BF1 7 0.9 ± 0.1 1.1 ± 0.4 1.8 ± 0.9
W/BF1→ W/BF1 2 0.8 0.8 0.6
*5  105 responder spleen cells were cultured with 5  105 irradiated stimulator spleen cells. Proliferation was measured by uptake of [3H]thymi-
dine. Stimulation index value = mean cpm of bone marrow transplant recipient + stimulator cells/mean cpm of recipient + autologous cells. Results
are reported as mean index value ± 1 SD. TCDM indicates T-cell–depleted bone marrow; HSC, hematopoietic stem cell.
Figure 4. Primary sheep red blood cell (SRBC) titer of W/BF1 recipi-
ents of bone marrow preparations. Primary antibody responsiveness
was evaluated by agglutination of SRBCs by serum from transplant
recipients in a microtiter assay. Data represent the results of individual
mice from the indicated transplantation group. Bars represent mean
values for each group. TCDM indicates T-cell–depleted bone marrow;
HSC, hematopoietic stem cell.
Figure 5. Anti–double-stranded DNA (dsDNA) autoantibody
levels of W/BF1 recipients of bone marrow preparations. Autoantibody
levels were determined using an enzyme-linked immunosorbent assay.
Ten- to 12-week-old male B6C3/F1 and BALB/c mice were used as
negative controls, and 20- to 24-week-old male W/BF1 and MRL/L
mice were used as positive controls. Bars represent mean values for
each group. *Five MRL/L samples were tested, with 1 measuring 1.572
optical density and the remaining 4 registering out of range. TCDM
indicates T-cell–depleted bone marrow; HSC, hematopoietic stem cell.
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Analysis of Autoimmune Disease Status of W/BF1
Recipients
The development of autoimmune disease, or the
absence thereof, was examined by the level of circulating
autoantibodies in posttransplantation mice. Normal
B6C3/F1 and BALB/c mice served as negative controls, and
aged W/BF1 and MRL/L mice served as positive controls.
The mean level of anti-dsDNA autoantibodies was low in
both B6C3/F1 and BALB/c mice (Figure 5). The mean level
of anti-dsDNA autoantibodies in both W/BF1 and MRL/L
mice was increased 6-fold over that seen in normal mice.
W/BF1 mice with allogeneic transplants from B6C3/F1
donors demonstrated significantly reduced levels of anti-
dsDNA autoantibodies. Mean antibody levels remained ele-
vated in W/BF1 mice that received syngeneic transplants,
regardless of the preparative protocol.
The mean level of anti-CLP autoantibodies was low in
both B6C3/F1 and BALB/c mice (Figure 6). The mean level
of anti-CLP autoantibodies in both W/BF1 and MRL/L
mice was increased 5-fold over that in normal mice. W/BF1
mice that received allogeneic transplants from B6C3/F1
donors demonstrated significantly reduced levels of anti-
CLP autoantibodies. Mean antibody levels remained slightly
elevated in W/BF1 mice with syngeneic transplants, regard-
less of the preparative protocol.
Fresh frozen sections of heart, kidney, liver, and lung tis-
sue were prepared from W/BF1 transplant recipients 100 days
posttransplantation and examined for pathological changes
and for the deposition of immune complexes, speciﬁcally in
the small coronary vasculature and glomeruli. Aged W/BF1
and adult B6C3/F1 mice were used as controls. In marked
contrast to aged W/BF1 controls, W/BF1 mice with allo-
geneic transplants from B6C3/F1 donors had no evidence of
CVD or glomerulonephritis, as was seen in normal B6C3/F1,
regardless of the preparative protocol used (Table 3).
DISCUSSION
Several studies have provided data indicating that the
dysregulation of the immune system that allows for the
development of systemic autoimmunity resides within the
HSC compartment [19-21]. It has been demonstrated that
the transplantation of normal WBM to major histocompati-
bility complex (MHC)-matched autoimmune-prone mice
can prevent the development of, and in some instances
effectively treat, autoimmune disease. Likewise, the trans-
plantation of WBM from autoimmune-prone mice to
MHC-matched autoimmune-resistant mice will often
induce systemic autoimmunity [18,22-24].
Over the past several decades, numerous animal models
have been used for studies of systemic and organ-specific
autoimmune diseases. W/BF1 mice are increasingly used as a
murine model for systemic autoimmune disease, most
notably human SLE. The progression of autoimmunity is
markedly more rapid and severe, and occurs at a signifi-
cantly higher rate of incidence, in the W/BF1 mouse than in
other autoimmune strains, such as MRL/L or either of the
W/BF1 parental strains, NZW and BXSB [1,12]. The
W/BF1 mouse is further distinguished by the signiﬁcant lev-
els of degenerative CVD and glomerulonephritis that result
from the deposition of immune complexes in the small
coronary vessels and glomeruli of affected animals. The
W/BF1 mouse presents a difﬁcult model for studies of lupus
nephritis, because the glomerular pathology is somewhat
delayed compared with coronary pathology. Additionally,
the mice begin to die from the effects of CVD/MI at
approximately 12 weeks of age, before the development of
fulminant nephritis. The W/BF1 mouse does, however, pro-
vide a useful model for studies of the cardiovascular compli-
cations of SLE. Degenerative CVD is directly correlated
with increased incidence of multiple MIs and subsequent
Table 3. Histopathology Grades of W/BF1 Recipients of Bone Marrow Transplants*
B6C3/F1 Aged WB/F1 TCDM Transplantation HSC Transplantation
n 3 3 3 3
Coronary vascular disease 0.67 ± 0.58 2.67 ± 0.52 0.33 ± 0.58 0.33 ± 0.58
Glomerulonephritis 0.67 ± 0.58 2.33 ± 0.58 0.33 ± 0.58 0.33 ± 0.58
*Histology grades were determined by periodic acid-Schiff scoring according to the method described by Berden et al. [12]. Ten- to 12-week-
old male B6C3/F1 mice were used as negative controls, and 20- to 24-week-old male W/BF1 mice were used as positive controls. Results are
reported as mean scores ± 1 SD. TCDM indicates T-cell–depleted bone marrow; HSC, hematopoietic stem cell.
Figure 6. Anti-cardiolipin autoantibody levels of W/BF1 recipients of
bone marrow preparations. Autoantibody levels were determined using
an enzyme-linked immunosorbent assay. Ten- to 12-week-old male
B6C3/F1 and BALB/c mice were used as negative controls, and 20- to
24-week-old male W/BF1 and MRL/L mice were used as positive con-
trols. Bars represent mean values for each group. TCDM indicates 
T-cell–depleted bone marrow; HSC, hematopoietic stem cell.
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mortality. Circulating immune complexes have been impli-
cated in CVD in human patients with SLE. Up to 60% of
patients with SLE have anti-CLP autoantibodies [11,13,25].
The pathology and progression of autoimmune disease
have been well characterized in the W/BF1 mouse after 12
weeks of age [8,11-13]. Our study sought to determine if
TCDM or HSC puriﬁed from WBM could be used to fully
reconstitute the immune system of male W/BF1 mice before
the onset of systemic autoimmune disease, thereby prevent-
ing CVD and subsequent mortality. Haploidentical, male
B6C3/F1 mice served as normal, non–autoimmune-prone
donors. Preliminary studies demonstrated that early signs of
disease were seen inconsistently from 8 to 10 weeks of age,
but onset of overt disease was evident between 10 and 12
weeks of age and progressed rapidly thereafter. Untreated
W/BF1 mice began to die from CVD/MI between 12 and 14
weeks of age (data not shown). As a result, 6- to 8-week-old
male W/BF1 mice were selected for transplantation.
A wide variety of protocols for processing marrow cells
have been used for BMT [17,26-28]. It was the intent of the
present investigation to use HSC puriﬁcation in an attempt
to successfully engraft W/BF1 mice and thus prevent both
serious graft-versus-host disease (GVHD) and the develop-
ment of CVD in the mice. In the ﬁrst preparation, T cells
were removed from WBM by a single round of Thy1 deple-
tion. Two rounds of Thy1 depletion, as is commonly used in
preparations for cellular assays, were not performed because
it has been demonstrated that the presence of a small num-
ber of T cells enhances engraftment and may ameliorate
adverse consequences of GVHD [29]. Fraction 2, low-den-
sity cells were further puriﬁed by selection of lineage-nega-
tive, CD71– cells with immunomagnetic beads. True
pluripotent HSC would be undifferentiated cells and would
be devoid of lineage-speciﬁc cell-surface markers. Addition-
ally, HSCs, which have not yet entered the cell cycle and are
nonproliferating, as cells in G0 phase, would not express the
transferrin receptor CD71. A preliminary flow cytometric
analysis of the stem cell preparation indicated a relative
absence of lineage markers (65% to 100%) with no
detectable CD71+ cells.
When transplanted with haploidentical BM from
B6C3/F1 donors, W/BF1 mice survived at an mean rate of
80 to 100 days posttransplantation (Figure 1). B6C3/F1 and
W/BF1 murine strains are haploidentical in that they are
matched at 1 MHC locus, H-2Kb, and mismatched at the
remaining, codominantly expressed, MHC locus. W/BF1
mice express an H-2Kz haplotype, whereas B6C3/F1 mice
express an H-2Kk haplotype. W/BF1 mice given TCDM
from B6C3/F1 donors exhibited lasting engraftment at a fre-
quency of 83% (Table 1). The slightly decreased value for H-
2Kk in W/BF1 recipients is caused by the inclusion of the
single nonengrafted mouse into the calculations of the mean.
When challenged in vitro with ConA, B6C3/F1 and
BALB/c mice responded vigorously (Figure 2). W/BF1 mice
that were not transplanted exhibited a muted response. This
diminished immunologic responsiveness by W/BF1 mice was
seen throughout the present study and would indicate that
the nature of the autoimmune disease in W/BF1 mice is not
B-cell speciﬁc, as may have been inferred from elevated levels
of autoantibodies found in aged W/BF1 mice. However, when
reconstituted with either TCDM or HSC preparations,
W/BF1 BM recipients responded to ConA challenge at a level
similar to that of either normal B6C3/F1 or BALB/c mice, ie,
the T-cell profile of B6C3/F1 donors. In contrast, W/BF1
recipients of BM preparations from W/BF1 donors remained
deﬁcient in responses to ConA challenge, ie, the proﬁle of
aged W/BF1 mice. Unlike the diminished T-cell response to
ConA challenge, response of control W/BF1 mice to chal-
lenge with LPS was equivalent to the responses of normal
B6C3/F1 and BALB/c mice (Figure 3). Reconstitution of
W/BF1 with either TCDM or HSC preparations from
B6C3/F1 donors resulted in no significant change in the
response to LPS. As such, W/BF1 recipients of either TCDM
or HSC preparations mounted impressive cellular responses
to mitogenic challenge by ConA or LPS, indicating reconsti-
tution and correction of the defective cellular immunologic
function normally found in the mice of this hybrid.
In mixed lymphocyte reactions, W/BF1 controls exhib-
ited a somewhat limited response to antigens from B6C3/F1.
This may be related to the demonstrated immunodeﬁciency
of W/BF1 mice revealed upon repeated stimulation with
B6C3/F1 antigens. B6C3/F1 controls, however, responded
to W/BF1 cells in a manner similar to the response seen to
BALB/c antigens. Thus, B6C3/F1 mice appeared to be more
capable of distinguishing between self and haploidentical-
nonself than were W/BF1 mice. W/BF1 recipients of
TCDM from B6C3/F1 donors were tolerant of self, tolerant
of donor, and fully reactive to antigens of an unrelated third
party, BALB/c (Table 2). These results indicate functional
reconstitution of the immune system in addition to toler-
ance of engrafted donor marrow. Although W/BF1 recipi-
ents of TCDM from W/BF1 donors had diminished respon-
siveness to third-party antigens, the statistical signiﬁcance of
these results could not be determined because of the low
numbers of TCDM recipients available for assay. W/BF1
recipients of HSC preparations from B6C3/F1 donors were
tolerant of self, tolerant of donor, and only slightly less reac-
tive to unrelated third-party antigens than were recipients of
TCDM. This slightly lower reactivity may be attributable to
a delay in immunologic reconstitution of recipients of trans-
planted HSC compared to WBM or TCDM.
Primary antibody responsiveness was evaluated by
development of agglutinins to SRBC revealed in a
microtiter assay 5 days after a primary immunization with
SRBC. As noted in the discussion of mitogenic challenge
and mixed lymphocyte reactions, nontransplanted W/BF1
mice appear to be dysfunctional in a wide array of immuno-
logic responses. In marked contrast, W/BF1 recipients of
both TCDM and HSC preparations from B6C3/F1 donors
responded regularly to SRBC challenge with an antibody
response that approached the proﬁle exhibited by B6C3/F1
and BALB/c controls. These results indicate that restoration
of fully functioning humoral immunity is achieved by trans-
plantation of the normal BM from haploidentical non–
autoimmune-prone donors.
Preliminary studies demonstrated normal autoantibody
levels in W/BF1 mice at the time of transplantation, age 6
to 8 weeks. W/BF1 recipients of both TCDM and HSC
preparations from B6C3/F1 donors exhibited markedly
reduced autoantibody levels compared with those of the
positive controls. Results were most impressive in recipi-
ents of allogeneic HSC preparations: their mean anti-
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dsDNA autoantibody levels were not statistically different
from those of normal controls (Figure 5). In contrast,
mean anti-dsDNA autoantibody levels of W/BF1 recipients
of both types of BM preparations from W/BF1 donors
remained markedly elevated and similar to those seen in
the positive controls, confirming functional immune
reconstitution, despite pretransplantation treatment with
radiation and myeloablation.
Likewise, anti-CLP autoantibody levels were dramati-
cally reduced to normal levels in W/BF1 recipients of
TCDM and HSC preparations from B6C3/F1 donors (Fig-
ure 6). Antibodies to dsDNA are consistently seen in
autoimmune models, and tissue damage caused by these
antibodies is more systemic and less tissue speciﬁc. Antibod-
ies to CLP are seen in relatively few autoimmune models,
specifically those models in which the mice suffer from
autoimmune cardiomyopathies. Because of the tissue-spe-
cific nature of anti-CLP autoantibodies, more posttrans-
plantation time, as much as an additional 100 days, may be
necessary for these autoantibodies to reach the levels
observed in aged W/BF1 controls. Overall levels of autoanti-
bodies were significantly reduced in W/BF1 recipients of
allogeneic BM preparations from B6C3/F1 donors.
Fresh frozen sections of heart, kidney, liver, and lung
were examined for pathological changes and for the deposi-
tion of immune complexes, speciﬁcally in the small coronary
vasculature and glomeruli. Although a minimal PAS-positive
staining was present in both the small coronary vessels and
glomeruli of normal B6C3/F1 controls, these deposits were
signiﬁcantly smaller and notably fewer than those in W/BF1
controls (Table 3). Likewise, the syngeneic posttransplanta-
tion histology of both strains was consistent with the respec-
tive untransplanted controls. The extent of CVD, as indi-
cated by PAS-positive deposits, in W/BF1 recipients of
TCDM and HSC preparations was actually slightly lower,
although not signiﬁcantly lower, than that in B6C3/F1 con-
trols. These results demonstrate the absence of degenerative
CVD in W/BF1 recipients of allogeneic BMT. Likewise,
PAS-positive deposits in the glomeruli of W/BF1 recipients
of TCDM and HSC preparations from B6C3/F1 donors
were slightly lower than those seen in B6C3/F1 controls,
demonstrating the absence of glomerulonephritis in allo-
geneic transplant recipients of marrow preparations from
non–autoimmune-prone mice. The incidence of immune
complex deposition, as indicated by DAB deposits in
immunohistochemical preparations, was closely correlated to
the extent of PAS-positive deposits. In untransplanted
W/BF1 populations of equivalent age to the mice examined
posttransplantation (20-22 weeks), all mice would be
expected to be in advanced stages of autoimmune disease,
with relatively few survivors.
This study demonstrates, for the ﬁrst time, the preven-
tion of degenerative CVD in autoimmune-prone male
W/BF1 mice by the transplantation of haploidentical
TCDM or HSC preparations. Although the results of
TCDM and HSC transplants were generally comparable,
HSC transplants provided a slight advantage with respect to
survival and engraftment. Additional study of posttransplan-
tation immunologic reconstitution and functional restora-
tion, for as much as 200 days after transplantation, may be
warranted as a means of clarifying borderline or ambiguous
observations, eg, the diminished cellular immune function
of the syngeneic BM recipients, the lower-than-anticipated
anti-CLP autoantibodies, and the anomalous response to
LPS of B6C3/F1 recipients of allogeneic BM. Closer exami-
nation of the progression and development of autoimmunity
in a previously nonautoimmune strain, such as B6C3/F1,
may provide additional information concerning the relation-
ship between autoimmunity, which arises from a genetic
predisposition, and the effect of host inﬂuences, including
thymic education, induction of tolerance, and other as-yet-
undefined influences on the engrafted hematopoietic and
immunologic cellular systems.
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